# GGPS1

## Overview
Geranylgeranyl diphosphate synthase 1 (GGPS1) is a gene that encodes the enzyme geranylgeranyl diphosphate synthase 1, a key player in the isoprenoid biosynthetic pathway. This enzyme is classified as a trans-prenyltransferase and is responsible for the synthesis of geranylgeranyl diphosphate (GGPP) from farnesyl pyrophosphate (FPP), a critical step in the mevalonate pathway (Foley2020GGPS1; Sang2020Ggps1). GGPP serves as a substrate for protein prenylation, a post-translational modification that is essential for the membrane localization and function of various proteins, including small GTPases involved in cellular signaling and dynamics (Foley2020GGPS1). The GGPS1 protein is predominantly expressed in the cytosol and is associated with organelles, playing a significant role in maintaining cellular processes such as cholesterol synthesis and membrane dynamics (Foley2020GGPS1). Mutations in the GGPS1 gene have been linked to a syndrome characterized by muscular dystrophy, hearing loss, and ovarian insufficiency, highlighting its clinical significance (Foley2020GGPS1). Additionally, GGPS1 expression levels have prognostic implications in certain cancers, such as oral squamous cell carcinoma (Huang2023The).

## Structure
The human geranylgeranyl diphosphate synthase 1 (GGPS1) protein is characterized by a specific molecular structure that facilitates its function in the isoprenoid biosynthetic pathway. The primary structure of GGPS1 includes conserved amino acid motifs, such as the aspartate-rich DDXX(XX)D sequences, which are crucial for its enzymatic activity (Kainou1999Identification). The secondary structure is predominantly composed of α-helices, forming a helical bundle that surrounds a central cavity where the active site is located (Kavanagh2006The).

The tertiary structure of GGPS1 is compact and globular, featuring an all α-helical trans-prenyltransferase fold. This structure is essential for the enzyme's catalytic function, as it facilitates the binding of substrates and cofactors (Kavanagh2006The). The quaternary structure of GGPS1 in mammals is typically hexameric, consisting of three dimers arranged in a propeller-like configuration, although octameric forms have also been observed in solution (Kavanagh2006The).

The enzyme's active form is stabilized by the carboxyl-terminal region, which is indispensable for substrate binding and catalysis (Matsumura2007The). GGPS1 may undergo post-translational modifications, such as phosphorylation, which can influence its activity and function.

## Function
The GGPS1 gene encodes the enzyme geranylgeranyl diphosphate synthase 1, which plays a crucial role in the mevalonate pathway by synthesizing geranylgeranyl diphosphate (GGPP) from farnesyl pyrophosphate (FPP) (Foley2020GGPS1; Sang2020Ggps1). GGPP is essential for the prenylation of proteins, a post-translational modification that attaches a hydrophobic lipid tail to proteins, facilitating their membrane anchorage and precise subcellular localization (Foley2020GGPS1). This process is vital for the function of small GTPases, such as those in the Rho and Ras/Rab families, which are involved in various cellular processes, including membrane tagging and cytoskeletal dynamics (Foley2020GGPS1).

In healthy cells, GGPS1 is expressed in the cytosol and is associated with organelles and the perinuclear region. It localizes prominently to the Z disc in muscle cells, a structure important for muscle contraction (Foley2020GGPS1). The enzyme forms a hexamer and is involved in maintaining the necessary levels of GGPP for cellular processes, ensuring proper protein prenylation and function (Foley2020GGPS1). This activity is crucial for various physiological processes, including cholesterol synthesis, cell signaling, and membrane dynamics (Sang2020Ggps1).

## Clinical Significance
Mutations in the GGPS1 gene are linked to a syndrome characterized by early-onset muscular dystrophy, sensorineural hearing loss, and primary ovarian insufficiency. This condition is associated with biallelic mutations in GGPS1, which impair the enzyme's activity, leading to a unique clinical phenotype. Patients exhibit symptoms such as muscle weakness, elevated creatine kinase levels, respiratory insufficiency, scoliosis, and progressive muscle weakness, which can lead to wheelchair dependence. Sensorineural hearing loss is often the first symptom identified, and primary ovarian insufficiency is present in all post-pubertal females (Foley2020GGPS1).

In addition to its role in this syndrome, GGPS1 expression levels have prognostic significance in oral squamous cell carcinoma (OSCC). High GGPS1 expression in tumor tissues is associated with poorer overall survival, disease-specific survival, and progression-free survival outcomes. GGPS1 is identified as an independent predictor of poor prognosis in OSCC, with its expression linked to pathways involved in cancer progression (Huang2023The).

GGPS1 deficiency also affects reproductive health, particularly in the uterus, where it leads to dystocia due to impaired uterine contractions. This is linked to disruptions in the RhoA/Rock2/p-MLC pathway, crucial for uterine function (Sang2020Ggps1).

## Interactions
GGPS1, or geranylgeranyl diphosphate synthase 1, is involved in the synthesis of geranylgeranyl diphosphate, a key intermediate in the isoprenoid biosynthetic pathway. It interacts with various proteins, playing a crucial role in protein prenylation, a post-translational modification process essential for the membrane localization and function of certain proteins. GGPS1 has been shown to interact with proteins such as farnesyl diphosphate synthase (FDPS) and is involved in the regulation of small molecule metabolic processes and cholesterol metabolic processes (Huang2023The).

The enzyme forms a hexameric structure, which is significant for its function and interaction with other molecules. This hexameric arrangement involves specific subunit interactions and is stabilized by magnesium ions and pyrophosphate moieties, which are crucial for its catalytic activity (Kavanagh2006The). GGPS1 also interacts with magnesium ions and pyrophosphate moieties through specific residues, which are essential for its enzymatic function and structural integrity (Kavanagh2006The).

In the context of disease, mutations in GGPS1 can disrupt its interactions, leading to conditions such as muscular dystrophy, hearing loss, and ovarian insufficiency. These mutations may impair the geranylgeranylation of small GTPases, affecting organelles involved in autophagy and mitochondrial dynamics (Foley2020GGPS1).


## References


[1. (Huang2023The) Ke Huang, Liang Han, Huimei Xu, Ruiming Xu, Hao Guo, Huihui Wang, and Zhaoqing Xu. The prognostic role and metabolic function of ggps1 in oral squamous cell carcinoma. Frontiers in Molecular Biosciences, March 2023. URL: http://dx.doi.org/10.3389/fmolb.2023.1109403, doi:10.3389/fmolb.2023.1109403. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2023.1109403)

[2. (Kavanagh2006The) Kathryn L. Kavanagh, James E. Dunford, Gabor Bunkoczi, R. Graham G. Russell, and Udo Oppermann. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. Journal of Biological Chemistry, 281(31):22004–22012, August 2006. URL: http://dx.doi.org/10.1074/jbc.m602603200, doi:10.1074/jbc.m602603200. This article has 134 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m602603200)

[3. (Matsumura2007The) Y. Matsumura, T. Kidokoro, Y. Miyagi, N. R. Marilingaiah, and H. Sagami. The carboxyl-terminal region of the geranylgeranyl diphosphate synthase is indispensable for the stabilization of the region involved in substrate binding and catalysis. Journal of Biochemistry, 142(4):533–537, July 2007. URL: http://dx.doi.org/10.1093/JB/MVM162, doi:10.1093/jb/mvm162. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/JB/MVM162)

[4. (Sang2020Ggps1) Yong-Juan Sang, Qiang Wang, Feng Zheng, Yue Hua, Xin-Ying Wang, Jing-Zi Zhang, Kang Li, Hai-Quan Wang, Yue Zhao, Min-Sheng Zhu, Hai-Xiang Sun, and Chao-Jun Li. Ggps1 deficiency in the uterus results in dystocia by disrupting uterine contraction. Journal of Molecular Cell Biology, 13(2):116–127, December 2020. URL: http://dx.doi.org/10.1093/jmcb/mjaa066, doi:10.1093/jmcb/mjaa066. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/jmcb/mjaa066)

[5. (Foley2020GGPS1) A. Reghan Foley, Yaqun Zou, James E. Dunford, Jachinta Rooney, Goutam Chandra, Hui Xiong, Volker Straub, Thomas Voit, Norma Romero, Sandra Donkervoort, Ying Hu, Thomas Markello, Adam Horn, Leila Qebibo, Jahannaz Dastgir, Katherine G. Meilleur, Richard S. Finkel, Yanbin Fan, Kamel Mamchaoui, Stephanie Duguez, Isabelle Nelson, Jocelyn Laporte, Mariarita Santi, Edoardo Malfatti, Thierry Maisonobe, Philippe Touraine, Michio Hirano, Imelda Hughes, Kate Bushby, Udo Oppermann, Johann Böhm, Jyoti K. Jaiswal, Tanya Stojkovic, and Carsten G. Bönnemann. <scp>ggps1</scp> mutations cause muscular dystrophy/hearing loss/ovarian insufficiency syndrome. Annals of Neurology, 88(2):332–347, June 2020. URL: http://dx.doi.org/10.1002/ana.25772, doi:10.1002/ana.25772. This article has 25 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/ana.25772)

[6. (Kainou1999Identification) Tomohiro Kainou, Kei Kawamura, Katsunori Tanaka, Hideyuki Matsuda, and Makoto Kawamukai. Identification of the ggps1 genes encoding geranylgeranyl diphosphate synthases from mouse and human. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1437(3):333–340, March 1999. URL: http://dx.doi.org/10.1016/s1388-1981(99)00028-1, doi:10.1016/s1388-1981(99)00028-1. This article has 28 citations.](https://doi.org/10.1016/s1388-1981(99)00028-1)